Your PSA doubling time indicates the rate at which your PSA level is rising and is one of the most important prognostic indicators following prostate cancer treatment. A PSADT of less than 3 months suggests very aggressive tumor biology, is strongly associated with the development of distant metastases, and is an independent predictor of prostate cancer-specific mortality. A PSADT of 3 to 10 months is concerning and typically prompts imaging studies (bone scan, CT, or PSMA-PET) and consideration of treatment escalation such as salvage radiation or androgen deprivation therapy. A PSADT of 10 to 15 months suggests moderately paced disease that may be suitable for close monitoring. A PSADT greater than 15 months indicates relatively indolent biology, and observation with serial PSA monitoring is often reasonable.

It is essential to note that PSADT calculations are most reliable when based on at least three PSA values over an adequate time interval. A two-point calculation, while commonly used, is more susceptible to PSA measurement variability and may not accurately represent the true kinetics of disease progression.

PSA doubling time is primarily used after definitive treatment for prostate cancer — radical prostatectomy or radiation therapy — when a rising PSA (biochemical recurrence) is detected. It helps distinguish patients with aggressive recurrences who need urgent salvage therapy from those with slow PSA rises who may safely be observed.

PSADT is also used during active surveillance for low-risk prostate cancer, where a rapidly shortening doubling time may trigger reclassification and recommend definitive treatment. In the setting of castration-resistant prostate cancer, PSADT helps assess the tempo of disease progression and guides decisions about initiating or changing systemic therapy.

PSADT assumes exponential PSA growth, which is a simplification. Actual PSA kinetics can be non-linear, especially early after treatment when benign sources of PSA (residual prostate tissue, prostatitis) may contribute to fluctuations. A PSA bounce after radiation therapy — a transient rise followed by a decline — can produce misleading PSADT values if measured during this period.

The calculation requires a rising PSA (PSA2 greater than PSA1). If PSA is stable or declining, PSADT is not applicable. Additionally, very low absolute PSA values (less than 0.1 ng/mL) are near the lower limit of assay sensitivity, and small measurement errors can dramatically affect the calculated doubling time.

PSADT should be interpreted alongside other clinical factors including Gleason score, pathological stage, time from treatment to biochemical recurrence, and imaging findings. A short PSADT with negative imaging may warrant a different approach than a short PSADT with visible metastatic disease. The result is a prognostic indicator, not a treatment recommendation in isolation.